Oral GHS-R1a agonist used as a single-dose diagnostic test for adult GH deficiency.
Reference facts
- Also known as
- Macrilen, AEZS-130
- Category
- Growth Hormone & Ghrelin
- Mechanism of action
- Oral GHS-R1a agonist used as a single-dose diagnostic test for adult GH deficiency.
- Targets
- GHS-R1a
- Indications under research or approved
- Diagnosis of adult growth hormone deficiency
- Regulatory status (reference entry)
- FDA-approved (2017)
- Half-life
- ~4 hours
- Sequence notes
- Orally active tripeptidomimetic ghrelin receptor agonist.
- Molecular weight (Da)
- 535
- Originator / sponsor
- Aeterna Zentaris / Novo Nordisk
- First reported
- 2013
Primary References
Explore research articles about Macimorelin
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.